UNSPSC 51162337: Atropine/brompheniramine/phenyltoloxamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162337 Atropine/brompheniramine/phenyltoloxamine/pseudoephedrine is a Commodity code covering pharmaceutical products, though recent state and local activity under this code shows minimal alignment with the specific drug combination named — instead, jurisdictions are buying naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive procurement processes. State and local governments use this code area to solicit pharmaceutical inventory for health departments, county health facilities, and cooperative purchasing alliances serving multiple member agencies. The buying entities include county health departments, state departments of administration overseeing cooperative purchasing, and multi-state collaborative procurement groups. Vendors typically must comply with FDA requirements, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, maintain authorized wholesaler relationships with chargeback systems, and submit electronic data in standardized formats (NDC codes, SKUs, UPCs, and generic descriptions). Contracts often include fixed-fee or competitive-pricing structures with administrative fees, insurance requirements ranging from $2 million to $5 million in liability coverage, and multi-year terms with renewal options.

Activity under the code appears concentrated in Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, representing a multi-state collaborative vehicle spanning Minnesota and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response date (note: the due date appears inconsistent with the posting date, suggesting possible data error in the source). MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; evaluation weighting heavily favored price competitiveness at 75 percent, with fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format compliance (5 percent). The code shows limited recent state and local activity, and the opportunities posted do not closely match the specific pharmaceutical combination the code nominally describes.